Mixed Monoclonal Antibody Cocktail for Cancer Immunotherapy from China
This product is a blend of multiple monoclonal antibodies (e.g., pembrolizumab and nivolumab derivatives) designed for immunotherapy treatment of solid tumors. It falls under HTS 3002.14.00.90 as mixed immunological products not in measured doses or retail packaging, per chapter notes defining immunological products as peptides/proteins regulating immunological processes.
Duty Rate — China → United States
100%
Rate breakdown
9903.04.60100%Pharmaceuticals: patented pharma articles — 100% floor rate
9903.05.860%Universal product exemption (U.S. note 52(b))
9903.05.900%Articles already subject to Section 232 (steel/aluminum/copper + derivatives, autos + parts, wood, medium/heavy vehicles + parts, semiconductors, patented pharma) — U.S. note 52(f)
Import Tips
• Obtain FDA biologics license application (BLA) approval prior to import; provide lot-specific certificates of analysis
• Declare as mixed immunological product; avoid retail packaging to stay in 3002.14, include biotech process details